SCHEMBL6104697

SCHEMBL6104697

Cc1ccc(CN(C(=O)Cc2ccccc2)N2CCCCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CNR2 P34972 3/20 0.49
CNR1 P21554 1/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4206481 0.83 SIGMAR1 (0.46) MEN1KMT2ACNR2CNR1LMNA
SCHEMBL18429032 0.79 CHRM2 (0.50) LMNATDP1CHRM2CHRM4CHRM5
SCHEMBL9690903 0.77 CHRM2 (0.51) LMNATDP1CHRM2CHRM4CHRM5
SCHEMBL6630975 0.75 TDP1 (0.43) MEN1KMT2ALMNASMN1; SMN2TDP1
SCHEMBL6169050 0.75 ALDH1A1 (0.52) MEN1KMT2ALMNACHRM2CHRM3
SCHEMBL3703032 0.71 HTR2A (0.57) LMNAPKM
SCHEMBL7712884 0.70 AKT1 (0.44) KMT2AL3MBTL1CHRM2CHRM4CHRM5
SCHEMBL8459141 0.70 HRH3 (0.51) CNR2CNR1SIGMAR1TSHRCYP2C19
Toluene SCHEMBL5404912 0.69 TDP1 (0.53) MEN1KMT2ACNR2CNR1LMNA
SCHEMBL7545610 0.69 SIGMAR1 (0.52) MEN1KMT2ASMN1; SMN2L3MBTL1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194834-A1 Azacyclic compounds ACADIA PHARMACEUTICALS, INC. 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194834-A1 Azacyclic compounds HTR6, HTR5A, HNMT MEN1 710/4885KMT2A 1270/4885CNR2 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.